Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Longboard Pharmaceuticals to $46 from $25 and keeps an Outperform rating on the shares after the company announced positive topline data from the PACIFIC Study evaluating bexicaserin for seizures associated with a broad range of developmental and epileptic encephalopathies. The analyst says bexicaserin looks as efficacious as Fintelpa.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LBPH: